Koichi Taira

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 670 citations

Medicine, Oncology, Pharmacology +17

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Phase I/<scp>II</scp> trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (<scp>JCOG</scp>0807)

Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa et al. · Cancer Science · 2014 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15

Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis

Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami et al. · PLoS ONE · 2017 · 65 citations · Full text

Medicine, Immunology, Internal Medicine +17

Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii

Yuji Nadatani, Toshio Watanabe, Wataru Suda et al. · Scientific Reports · 2019 · 54 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +13